Bristol-Myers Squibb and Aveo to study new combination RCC therapy

Bristol-Myers Squibb has agreed to support Aveo Oncology in its efforts to evaluate a promising new combination therapy for renal cell carcinoma (RCC).

A clinical trial has commenced assessing Aveo's oral, once-daily, vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in combination with Bristol-Myers Squibb's anti-PD-1 therapy Opdivo in advanced RCC patients.

Bristol-Myers Squibb will supply Opdivo throughout the phase I/II Aveo-sponsored TiNivo trial. The phase I component will assess escalating doses, while the expanded phase II cohort will utilise the combination dose established by this process.

The trial will be led by the Institut Gustave Roussy in Paris under the direction of Professor Bernard Escudier, chairman of the Genitourinary Oncology Committee.

Dr Michael Needle, chief medical officer of Aveo, said: "We appreciate Bristol-Myers Squibb's support for this study, and we look forward to working with Dr Escudier and his team to fully understand this potential."

This comes after the company agreed to provide Bavarian Nordic with access to Opdivo for use in a new lung cancer clinical trial earlier this week.

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.